Aims Although methadone is widely used to treat opiate dependence, guidelines for its dosage are poorly defined. There is increasing evidence to suggest that a strategy based on plasma drug monitoring may be useful to detect non-compliance. Therefore, we have developed a population-based pharmacokinetic (POP-PK) model that characterises adaptive changes in methadone kinetics. Methods Sparse plasma rac-methadone concentrations measured in 35 opiate-users were assessed using the P-Pharm software. The final structural model comprised a biexponential function with first-order input and allowance for time-dependent change in both clearance (CL) and initial volume of distribution ( V ). Values of these parameters were allowed to increase or decrease exponentially to an asymptotic value. Results Increase in individual values of CL and increase or decrease in individual values of V with time was observed in applying the model to the experimental data. Conclusions A time-dependent increase in the clearance of methadone is consistent with auto-induction of CYP3A4, the enzyme responsible for much of the metabolism of the drug. The changes in V with time might reflect both up-and downregulation of a 1 -acid glycoprotein, the major plasma binding site for methadone. By accounting for adaptive kinetic changes, the POP-PK model provides an improved basis for forecasting plasma methadone concentrations to predict and adjust dosage of the drug and to monitor compliance in opiate-users on maintenance treatment.
Introduction kinetics [4, [11] [12] [13] .
We have previously used the population model Although methadone is widely used to treat opiate dependence in the US, Australia and much of Europe, approach in an attempt to define the single-dose kinetics of methadone in opiate users by augmenting the more guidelines for its optimal dosage are poorly defined. However, there is increasing evidence to suggest that a limited data (0-27 h sampling ) obtainable from such individuals with a richer data set from normal subjects strategy based upon the monitoring of plasma drug concentrations may be useful in this respect [1] [2] [3] [4] [5] [6] . This (0-57 h sampling ) [14] . Although it was possible to demonstrate that the kinetics of methadone were different is reinforced by a better understanding of the influence of incomplete compliance with dosage [1, 7] , the effects in the two groups of subjects, the study indicated that an accurate description of the time-course of plasma drug of supplementation of dosage with illicit methadone [7] , the role of variable metabolism of the drug and metabolic concentrations in opiate-users would require an extended sampling period and data from both single and continuous dosage. Thus, the current investigation extends our single-dose study in opiate users (0-27 h) to include data subjects), and accommodates adaptive changes in kinetics noted during the analysis of the G1 data set with respect to evaluation of the terminal elimination half-life [14] during the course of treatment. Hence, this refined model provides a more accurate basis for population-based which in turn could prevent full characterisation of methadone accumulation. Trough plasma drug concenforecasting methods to predict and adjust the dosage of methadone in opiate users on maintenance treatment.
trations were measured daily from day 2 to days 18-30 of treatment. Plasma concentrations of a 1 -acid glycoprotein were measured in serial trough samples from all Methods G3 patients. A total of 501 plasma concentration measurements, Subjects and protocols combined from all of the protocols, was used in the A total of 35 opiate users was studied after monitoring POP-PK analysis. for signs of opiate withdrawal using the Symptom Severity Assessment (SSA) chart [15] , and before commencing Sample collection methadone maintenance treatment. They were grouped according to three different protocols (G1, G2 and G3)
Pre-dose and trough blood samples were drawn by and combinations thereof. Demographic characteristics venepuncture; a butterfly cannula was placed in a forearm and a brief description of each protocol are given in vein to obtain samples during more intensive study Table 1 . The mean initial daily dose of rac-methadone periods (Protocols G1 and G2). All samples (10ml) were HCl was 39±16 s.d. mg (range 5-80 mg), given as Drug collected in heparinised Monovette collection tubes Tariff Formula (DTF) mixture; the mean final mainten-(Sarsted, Leicester UK). After centrifugation of the blood ance dose was 40±17 s.d. mg (range 5-80 mg). In for 5 min (1000 g) the plasma was transferred to polypropprotocols G1 and G2 oral intake of the drug was ylene tubes and stored at −20°C until assay. Pre-dose witnessed daily in the morning. A week's supply of urine samples (20 ml) were also collected on every visit methadone was dispensed to the subjects in protocol for routine drug screening purposes and their pH was G3. They were instructed to take one dose every measured. morning, rinsing the container and swallowing the residue. One subject reported that, on one occasion, he
Analytical methods took two doses together and missed the next day's dose. Another subject indicated that he divided the daily dose, Plasma (2 ml) was assayed for methadone by liquid chromatography as described previously [14] . The taking half in the morning and half in the afternoon. It was assumed that the other subjects adhered to the daily between-and within-day coefficient of variation of the assay at a methadone concentration of 100 ng ml −1 (and dosage regimen.
In protocol G1 6-10 plasma drug concentrations were 5 ng ml −1 ) were 9.5% and 3.5% (9.8% and 7.2%), respectively (n=10). Urine samples were screened for measured up to 27 h after a single dose of methadone in 17 subjects. One to two 24 h concentration-time profiles common drugs of abuse including opiates, cocaine, cannabinoids, benzodiazepines and amphetamines using (4-37 samples) were measured during days 6-37 of multiple dosing in 19 subjects in protocol G2. Of these an automated enzyme immunoassay (EMIT, Syva, Berkshire UK). Plasma concentrations of a 1 -acid glycoindividuals, eight were also included in G1 since they provided first dose profiles as well as data at steady-state.
protein were measured using an antibody reaction and nephelometry (Behring Diagnostics, Frankfurt). The Protocol G3 was designed to overcome shortcomings .
after their first dose of methadone and at steady-state (the eight subjects overlapping G1 and G2 protocols), a paired t-test was used to compare parameters. In addition, Data analysis superimposition of predicted and observed profiles (steady-state from first dose and vice versa) was examined As there were insufficient measurements in each subject to obtain estimates of individual PK parameters for in these subjects. Finally, all data (35 subjects) were analysed together. methadone by classical analysis, the population approach was applied using the P-Pharm software package (Version To investigate time-dependency in the values of pharmacokinetic parameters, the pooled data 1.4, SIMED, Creteil, France) run on a PC with a Pentium-90 processor. The algorithm in P-Pharm is (G1+G2+G3) were re-analysed after splitting them according to the time that blood sampling occurred after Bayesian in nature and is described as being of the twostage expectation-maximisation (EM) type [16] that was the first methadone dose. Therefore, the data from the 35 subjects were treated as if they effectively represented introduced for analysing incomplete data in the late 1970s [17] . Nevertheless, some consider the P-Pharm algorithm 58 subjects. Time bin (TB) was introduced as a new covariate, taking one of three values in each effective to be more like the iterative two-stage procedure proposed by Prévost [18] .
subject (I=0-120 h; II=120-300 h; III≥300 h). The statistical significance of adding this co-variate was The time-course of plasma methadone was described by a bi-exponential disposition function with first-order investigated using stepwise multiple regression, as implemented in P-Pharm, and an appropriate F value input since we had previously reported that this was superior to a structural model incorporating mono-(a=0.05).
Having detected time-dependency using TB as a exponential disposition [14] . The population model was the same as that described in our previous report [14] covariate, the phenomenon was then incorporated into the structural model. Thus, auto-induction of metabolism except that a log-normal rather than a normal distribution was assumed for all population pharmacokinetic paramwas accommodated by allowing the initial value of clearance (CL(0)) to increase mono-exponentially to an eters. The Kolmogorov-Smirnov test (embedded in P-Pharm) rejected normal distribution of the same asymptotic value (CL(ss)), as described by Levy et al. [19] (Equation 1, where k I is an induction rate constant). parameters with the present data set. Parameter estimates for individual subjects were obtained by the maximum a CL=CL(ss)−[CL(ss)−CL(0)]e
(1) posteriori probability (MAP) Bayesian fitting procedure within P-Pharm. In all analyses oral clearance (CL/F), Although Equation 1 defines an induction process, in practice, the value of CL could also decrease since CL(ss) central volume of distribution (V/F), the transfer rate constants between central and peripheral compartments was allowed to take values greater or less than CL(0). Absolute values of systemic clearance (CL) are indetermi-(k 12 , k 21 ), the apparent absorption rate constant (ka) and the absorption lag time (t lag ) were considered as primary nant from oral data alone since systemic availability ( F) is also a variable. Therefore, in order to implement parameters. Thus, a population geometric mean value and an estimate of its variability were obtained for each paramEquation 1, the value of F was arbitrarily set to 1 (experimentally determined values range from 0.79 to eter. The terminal elimination half-life (t 1/2 , z ) was considered as a secondary parameter. In this case, different 0.95 [11, 20] , and clearance was reported as the hybrid term CL/F. population values could be calculated depending upon the approach used [14] . Here, we report only the approximate However, it was still possible to assess relative change in CL under the assumption of constant F. Since the estimates of half-life and its variance obtained using individual values of kinetic parameters determined by the systemic clearance of methadone is reported to be much lower than hepatic blood flow [11, 20] , any time-MAP Bayesian fitting procedure. Age, sex, weight, methadone dose and urine pH were investigated as dependent change in F was considered likely to have relatively little effect on plasma drug concentrations covariates for CL (initial and steady-state) and V (initial and steady-state).
compared with a similar change in systemic clearance. Thus, for a low extraction drug such as methadone [21] The data from each protocol were analysed both separately and grouped. Pharmacokinetic parameters a large change in first-pass metabolism would be reflected in a much smaller change in systemic availability. derived from the steady-state data (19 G2 subjectsexcluding data from the first dose-plus 7 G3 subjectsNevertheless, in the absence of data to allow characterisation of the drug elimination rate (i.e. when only single excluding data prior to 120 h) were compared with those estimated from first dose (17 G1 subjects) using the Z-test. trough concentrations are available) any change in CL would have the same effects as F, but in the opposite 8.79 l h −1 (147 ml min −1 ) for CL/F and 153 l for V /F; the estimate of the mean terminal elimination half-life direction. Change in CL and F are distinguishable only when multiple samples are taken (as in protocol G2) was 35 h. Covariate analysis indicated that CL/F was inversely related to urine pH (Equation 2), although it since a change in CL will influence the elimination rate but a change in F will not. Therefore, time-dependent explained only 27% of the variance: change in F as an alternative to and in addition to that CL/F (l h −1 )=22.1−2.1×pH (2) in CL was investigated using a function analogous to Female opiate users had higher values of V/F and this Equation 1. Similarly, the influence of a time-dependent parameter was directly related to weight. Sex and weight change in V was assessed, alone and in combination with (Equation 3) together explained 33% of the variance in changes in CL and F. The values of the rate constants V /F: defining the changes in CL, V and F with time were allowed to vary independently.
Results

Model building
Time as a covariate The covariate designated TB (i.e. time
First-dose (G1) vs steady-state (G2+G3) data
The bin I=0-120 h; II=120-300 h; III≥300 h) was found population mean value of CL/F was significantly lower to be a significant determinant of CL ( P<0.007; ( P<0.05) in subjects at the start of methadone treatcoefficient of TB=1.06). Thus, assuming that all other ment (G1) than in those at steady state (G2+G3). This parameters remained constant, CL increased by 1.06 l h −1 change in clearance was also confirmed by an increase for each successive time category (I-III). This trend for a ( P<0.0001) in the a posteriori estimate of this parameter time-dependent increase in CL was also apparent on from first dose to steady-state in the eight subjects visual inspection of pooled data (not shown), despite the included in both G1 and G2 protocols. In addition, these fact that the time categories included different subjects. subjects showed mean decreases in V/F ( P<0.03) and Profiles in those individuals with data in 2-3 of the time ka (P<0.02) and a decrease in terminal elimination halfcategories show this change more clearly (Figure 2 ). life ( P<0.0001). Accordingly, their full multiple dose plasma drug concentration-time profiles were not super-
The final model imposable whether predicted from the initial first dose or from steady-state data (Figure 1) .
Incorporation of adaptive kinetics into the population model
Addition of the parameters CL(ss) and k I , defining autoinduction of methadone metabolism, to the original Pooled data (G1+G2+G3) Ignoring any time dependent changes, the overall mean population values were model improved its ability to predict the experimental incorporating time-dependence in V without change in CL and time-dependence in F with and without change data, as indicated by maximum likelihood (-LL) and the in CL and/or V were investigated but produced inferior Akaike Information Criterion (AIC) [22] (Table 2) . The fits to those obtained using a time-dependent clearance. residual sum of squares was reduced from 2.825×10 4 to However, incorporation of time-dependence in both CL 2.445×10 4 (P=0.02, F test). and V (constant F) not only improved the general fit The revised model was considerably better at fitting significantly (Table 2 ), but described the larger than plasma drug concentrations in those individuals with both expected swings seen in some of the steady-state data single dose and steady-state profiles, predicting the trend (Figure 4c ). Addition of a lag time for induction did not for trough concentrations to increase and then decrease produce any further improvement (Table 2) . Thus, the with time to a steady value during constant daily dosing final model incorporated adaptive changes in both the (Figure 3) . Nevertheless, the fits to some individual data clearance and the distribution of methadone. The residual were still not satisfactory with respect to capturing the sum of squares was reduced from 2.445×10 4 to degree of oscillation of the plasma drug concentration at 1.768×10 4 ( P=0.01, F test) by using this model. Values steady state (Figure 4b) . A greater swing between maxiof the PK parameters for the model are reported in mum and minimum plasma drug concentrations at steady- Table 3 . The changes in CL and V commenced state than predicted from single dose data is indicative of immediately after the first exposure to the drug and were a decrease in distribution volume. Alternative models characterised by different and highly variable half-lives ( population geometric mean 120 h (range 34-600 h) for CL and t 1/2,z with values obtained from analysis of the data 1.1 fold. Some subjects (as discussed previously) showed a marked decrease in V with time. These various changes were accompanied by a decrease in the mean terminal elimination half-life from 128 h to 48 h. The mean value of plasma a 1 -acid glycoprotein concentration measured in the subjects of protocol G3 did not change significantly over time, although individuals showed both decreases and increases from the normal range (0.5-1.2 g l −1 ) (Figure 6 ).
Discussion
It has been suggested previously that the kinetics of methadone undergo adaptive changes during repeated administration of the drug. These changes have been variously attributed to an increase in clearance [4, [11] [12] [13] or volume of distribution, or to a decrease in systemic availability [11] . We have confirmed a time-dependence in the kinetics of methadone and have described it quantitatively with a kinetic model incorporating progressive changes in clearance and distribution of the drug. The mechanisms of these changes are unknown. However, since the metabolism of methadone has been shown in vitro to be mediated largely by CYP3A4 [8, 9, 23], an inducible enzyme, auto-induction of metabolism may be responsible for the increase in CL with time.
Marked increases in the maintenance dosage requirements for methadone in patients receiving rifampicin, a known inducer of CYP3A4, have been documented [24, 25] . A time-dependent decrease in the plasma concentrations of carbamazepine during continuous dosage is turnover [27] to account for the auto-induction of volume of distribution (experimental data are normalised for a carbamazepine [28] was used to describe our methadone daily dose of 10 mg methadone HCl). data. The model has been applied previously to account for both hetero-and auto-induction with respect to several drugs using classical pharmacokinetic analysis [19, using the model that assumed no time dependency are shown in Figure 5 . The average increase in CL/F from 27, 29-31]. Hussain & Posner [32] have also used a similar approach in a population kinetic analysis of the first dose of methadone to steady state was about 3.5 fold whereas, the average increase in V /F was only about lamotrigine, which appears to induce its own glucuronid- ation to a small extent [33] . In the analysis of Hussain & pine, and the induction of nortriptyline (mean value 140 h; range 48-284 h, [31] ) by pentobarbitone. Data for Posner [32] , the data were not stratified by time bin as an intermediate step in model building since their subjects the auto-induction of ifosfamide and cyclophosfamide, also substrates of CYP3A4, indicate shorter mean induchad a wide variation in exposure to lamotrigine over time. Hence, exposure time from the start of therapy was tion half-lives (9-10 h; range 2-158 h) [30] . In part, the differences between induction half-lives for the various examined as a covariate affecting clearance.
Drugs inducing the same enzyme should exhibit the substrates and their wide individual variation could reflect the influence of co-induction of other cytochromes P450 same induction half-life since the induction half-life is related to turn-over of the enzyme. However, the time with different turnover times. Methadone, for example, is metabolised by both CYP3A4 and, to a lesser extent, to reach the final steady-state of drug concentrations depends on the relative values of the rate constants for CYP1A2 [8] . Application of a model incorporating differential rates of induction would require a enzyme turnover and for elimination of the inducer [34] . Our mean value of 94 h (range 62-205 h) for the autobi-exponential function analogous to Equation 1 and more intensive plasma sampling during the induction induction half-life of methadone compares with similar values reported for the auto-induction of carbamazepine phase.
Most of the pharmacological effects of rac-methadone (mean value 106 h; range 53-282 h [19] ), the induction of clonazepam (mean value 72 h; range 20-146 h, [29] ) seem to reside in the R-isomer [35, 36] . Differences in the kinetics of the isomers have been reported, albeit and ethosuximide (range 85-806 h [27] ) by carbamazewith some disagreement as to their magnitude and direction [4, [36] [37] [38] [39] [40] . However, since CYP3A4 is the main enzyme responsible for the metabolism of both isomers [23] , it is unlikely that their metabolism undergoes a differential degree of induction. Indeed, Eap et al. [23] , despite observing wide inter-individual variation of R/S ratios, did not show any significant change in the intraindividual plasma R/S methadone concentration ratio during continuous treatment with the racemate. The changes in V with time supported by our final kinetic model are more difficult to account for than the increase in clearance. One hypotheses in this regard relates to changes in plasma protein binding. It has been shown that inducers of CYP3A4 such as phenobarbitone and rifampicin are also capable of up-regulating the the plasma binding of basic drugs [41, 42] . Since methadone appears to induce CYP3A4 and it is highly tivity in the kinetics of methadone enantiomers [4, 40] . Nevertheless, it is anticipated that the present model will bound to a 1 -acid glycoprotein [43] , its administration could cause a time-dependent decrease in its own volume be useful in association with plasma drug concentration monitoring and Bayesian forecasting to optimise methaof distribution. A time-dependent decrease in V in 12 of our subjects was consistent with this phenomenon. On done dosage, to detect incomplete compliance and illicit methadone ingestion, and to rationalise methadone the other hand, a mechanism whereby plasma binding might decrease, causing the volume of distribution of detoxification regimens using opioid antagonists. methadone to increase with time, as indicated in some of sampling times [14] . The present analysis suggests another Measuring compliance in methadone maintenance patients:
reason arising from the time-dependence of CL and V. [24] 1996; 9: 365-373. showing that while rifampicin increased the oral clearance ences in plasma drug binding [44, [47] [48] [49] and stereoselec-
